Research progress on antiplatelet drug therapy response and its relationship with CYP2C19 and APOE gene mutations in patients with chronic vascular diseases
Antiplatelet drugs for chronic vascular disease(CVD)have become an indispensable routine adjuvant treatment protocol.However,in patients who use antiplatelet drugs,adverse reactions such as resistance to antiplatelet drugs or the risk of bleeding often occur,not only affecting the efficacy,but also threatening the patient's life.Therefore,the safety of antiplatelet drugs is of great concern.Clinical data shows that there are significant differences between certain gene mutations and treatment outcomes in patients with CVD.Cytochrome P450 oxidase 2C19(CYP2C19)and apolipoprotein E(APOE)are mainly involved in platelet activity and the transformation and metabolism of lipoproteins.Their gene mutations are one of the important mechanisms leading to the differences in antiplatelet drug responses in CVD patients.In recent years,the characterization of CYP2C19 and APOE gene mutations in CVD,and their association with antiplatelet drugs have made many new advances.
万方数据
维普
